Potential use of synbiotics in ENT diseases

Abstract

Prevention of recurrent ARVI is an urgent medical and social problem, especially in children. In children of this group, an imbalance of the intestinal flora was detected, which can be leveled by oral administration of probiotics, which cause immunomodulatory effects. Normal micro-flora performs important physiological functions and are active against pathogenic and conditionally pathogenic microflora. The microbiota (a collection of microbes that colonize the human body) is affected by the environment, often leading to the development of SARS. In this case, the normal microflora has an antagonistic activity in relation to the pathogenic one. Useful bacteria are called probiotics (lactobacilli and bifidobacteria) and represent a treatment option for chronic respiratory dis-eases. During the recurrence of acute respiratory infections (ROIDP), intestinal flora dysbiosis is detected, which can be improved by the use of probiotics. Known diseases that disrupt the function of normal microflora, causing dysbiosis. There are microorganisms that violate the permeability of the epithelial barrier of the mucous membrane. Dysbiosis can be regu-lated by probiotics that are administered both orally and nasally. They can have various immunomodulatory effects. Prebiotics are an indigestible form of fiber. A combination of Pro-and prebiotics is a synbiotic that has a synergistic effect in the treatment of many diseases and reduces the frequency of all infectious diseases. New synbiotic dietary supplement contributes to the improvement of immunological mechanisms, mucosal immunity, enhance-ment of antiviral immunity, etc. It contains 5 probiotics and one prebiotic and is approved for use in children from the first month of life. This supplement has a positive effect on several immune system indicators in the treatment of sickly children. It may be recommended for dysbiosis, diabetes, coeliac disease and for the prevention of influenza and flu-like syndromes.